吉非替尼联合康莱特注射液治疗晚期非小细胞肺癌探讨  

Clinical efficacy of Gefitinib combined with KLT in treatment of advanced non-small-cell lung cancer

作　　者：张曙辉[1] 邹立新[1] 

机构地区：[1]长沙市第四医院血液肿瘤科,湖南长沙410006

出　　处：《现代肿瘤医学》2014年第12期2857-2859,共3页Journal of Modern Oncology

摘　　要：目的:探讨吉非替尼联合康莱特注射液治疗晚期非小细胞肺癌的临床疗效。方法:选取我院收治的非小细胞肺癌患者,随机分为观察组和对照组。对照组患者给予吉非替尼口服治疗,观察组患者在此基础上加用康莱特静脉滴注,两组患者均以治疗21天为一个疗程,治疗持续3个疗程。结果:治疗后观察组患者的治疗有效率(69.1%)和疾病控制率(87.3%)均高于对照组(47.3%、63.6%),治疗后观察组患者生活质量的改善率(52.7%)高于对照组(27.3%),差异均有统计学意义(P<0.05);而两组患者的毒副反应发生率间差异无统计学意义(P>0.05)。结论:吉非替尼联合康莱特注射液治疗晚期非小细胞肺癌效果显著,值得临床推广。Objective： To investigate clinical efficacy of Gefitinib combined KLT in treatment of advanced non-small- cell lung cancer. Methods： The patients with advanced non- small- cell lung cancer in our hospital were selected,and divided into control group and observation group. The patients in control group were treated with oral Gefitinib,and the patients in observation group received KLT intravenous infusion in addition. 21 days as a course of treatment,and all patients were treated for 3 courses. Results： The treatment efficiency（ 69. 1%） and the disease control rate（ 87. 3%） of observation group were higher than control group（ 47. 3%,63. 6%）,and differences were statistically significant（ P 0. 05）. There was no significant difference between the incidence of adverse reactions of the two groups（ P 0. 05）. Conclusion： The effect of Gefitinib combined KLT in advanced non- small cell lung cancer is significant.

关 键 词：吉非替尼 康莱特注射液 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]